Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Removal of tine-based leadless pacemakers - Insights from a large multicenter experience.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Integration of PRAETORIAN Score, Defibrillation Testing and Follow-Up Outcomes for the Assessment of Conversion Failure in Patients with Subcutaneous Implantable Cardioverter Defibrillator: results from the i-SUSI registry.

Heart rhythm·2026
Same author

Partner valves: role of a prospective device selection strategy using ACURATE and SAPIEN 3 as complementary devices in transcatheter aortic valve implantation.

Frontiers in cardiovascular medicine·2026
Same author

Reclassification of Exercise-Induced Arrhythmogenic Cardiomyopathy: Detection of a Pathogenic PKP2 Variant in a Male Athlete.

JACC. Case reports·2026
Same author

Electromagnetic interference during epicardial ablation in a patient with an extravascular implantable cardioverter-defibrillator and arrhythmogenic right ventricular cardiomyopathy: a case report.

European heart journal. Case reports·2026
Same author

Neural resilience improves survival in cardiovascular patients.

Cardiovascular research·2026

Related Experiment Video

Updated: May 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dronedarone reduces arterial thrombus formation.

Alexander Breitenstein1, Susanna H M Sluka, Alexander Akhmedov

  • 1Cardiovascular Center, University Hospital Zurich, Switzerland.

Basic Research in Cardiology
|October 12, 2012
PubMed
Summary
This summary is machine-generated.

Dronedarone effectively reduces arterial thrombus formation by inhibiting platelet aggregation and plasminogen activator inhibitor-1 (PAI1) expression. This suggests a beneficial pleiotropic effect beyond heart rate and blood pressure reduction.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

  • Cardiovascular Pharmacology
  • Thrombosis Research
  • Drug Discovery

Background:

  • Dronedarone is linked to fewer hospitalizations for acute coronary syndromes.
  • The precise mechanisms behind dronedarone's cardiovascular benefits are not fully understood.
  • Potential pleiotropic effects beyond heart rate and blood pressure reduction warrant investigation.

Purpose of the Study:

  • To investigate the role of dronedarone in arterial thrombus formation.
  • To elucidate the impact of dronedarone on key components of the coagulation and fibrinolytic systems.
  • To determine if dronedarone's antithrombotic effects occur at clinically relevant concentrations.

Main Methods:

  • Utilized a mouse photochemical injury model to induce arterial thrombosis in C57Bl/6 mice.
  • Administered dronedarone to mice and assessed carotid artery thrombus formation.
  • Measured thrombin- and collagen-induced platelet aggregation.
  • Quantified expression of plasminogen activator inhibitor-1 (PAI1) and tissue factor (TF) in the arterial wall.
  • Assessed coagulation using prothrombin time (PT) and activated partial thromboplastin time (aPTT).

Main Results:

  • Dronedarone significantly inhibited carotid artery thrombus formation in vivo.
  • Thrombin- and collagen-induced platelet aggregation were significantly impaired in dronedarone-treated mice.
  • Expression of plasminogen activator inhibitor-1 (PAI1) was reduced in the arterial wall of treated mice.
  • Tissue factor (TF) levels and coagulation times (PT, aPTT) remained unchanged.

Conclusions:

  • Dronedarone inhibits arterial thrombus formation through the combined effects of reduced platelet aggregation and decreased PAI1 expression.
  • These antithrombotic effects occur at concentrations achievable in patients.
  • Dronedarone may possess beneficial pleiotropic effects contributing to its cardiovascular protective profile.